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Nanjing Pharmaceutical Co.,Ltd (Brief in Nanjing Pharma,stock code 600713) 
was founded in 1951. It was the first public company in the pharmaceutical 
distribution industry listed in Shanghai Securities Exchange in 1996 and has become 
a trans-regional, group scale and network-type company. Its market covers provinces 
of Jiangsu、Anhui、Fujian and part of Shandong、Henan、Sichuan、and Xinjiang 
provinces etc,and it serves more than 46000 clients, among which are 200 level-3 
and 500 level-2 hospitals. Its compound annual growth rate (CAGR) reaches 38%. In 
consecutive 5 years, NPC is one of the top 5 enterprises of Chinese pharmaceutical 
industry; and top 1 pharmaceutical enterprise in Jiangsu province.  
Shanghai Pharmaceutical Co.,Ltd (Brief in Shanghai Pharma,stock code 
601607) , the biggest pharmaceutical enterprise in Shanghai, has absorbed Shanghai 
Industrial Pharma and Shanghai Zhongxi Pharma as part of a restructuring.It 
primarily operates in the following three business segments: Pharmaceutical business, 
Pharmaceutical distribution and supply chain solution and Pharmaceutical retail. It 
owns many famous trademarks such as Sine, 
Guangdongtianpu,Diyishenghua,Xinya,Changyao,Yaocai, Qingdaoguofeng, 
Huqingyutang, Zhengdaqingchunbao.It manufactures and markets a broad range of 
pharmaceutical products, spanning chemical drugs, biopharmaceutical products, 
Chinese medicines, medicinal chemicals and other pharmaceutical products. 
In this paper, we collected the information of background and operating status 
of the two public companies, and did a comparative analysis on the financial 
statements from 2006-2010.Through lateral and vertical coparison on main financial 
index such as operation compacity,profitability,currency creativity and historical 
trend analysis, we analyzed the basic financial indicators of two companies in 
accordance with their annual financial statements, and made a comparison of the 
financial statement from 2006 to 2010. Then we evaluated the financial strategy and 















with the financial analysis from above chapters, and finally made the conclusion and 
submitted a proposal. 
We believe that with the people’s health promotion and an aging population, the 
pharmaceutical industry is facing a tremendous growth opportunities. Second 
Five-national pharmaceutical industry clearly to speed up the development of 
structural and increase industry concentration, This giveNanjing Pharmaceutical 
and Shanghai Pharmaceutical a great opportunities. Financial analysis of the results 
from the two companies has been to seen thatShanghai Pharmaceutica keep ahead. It 
's financial status and profitability are more than the Nanjing Pharmaceutical . 
Nanjing Pharmaceutical’s profitability is still relatively weak, less able to value 
creation, companies should look for other strategic partners as soon as possible, and 
obtain financing from in the capital marketsto accelerate the acquisition to expand 
and improve profitability. 
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1978 年至 2008 年，历经 30 年改革大潮洗礼的中国医药行业发生了翻天覆
地、日新月异的变化。30 年来，中国医药工业增长速度一直高于国内生产总值
（GDP）。从 1978 年到 2007 年，医药工业产值年均递增 16.8%，成为国民经济中
发展 快的行业之一。2009 年 1-12 月，我国医药行业累计实现销售产值 9915.9
亿元，同比增长 21.4%；2009 年 1-12 月，我国医药行业整体产销率为 95.5%，
同比提高 0.15 个百分点。2010 年 1-8 月，我国医药制造业资产总计达 10,236.85
亿元，同比增长 19.47%；实现营业收入 6976.15 亿元，同比增长 25.69%；利润







                                                             






































































































图 1- 1 南京医药公司股权及实际控制人关系图 
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